GlassScriptPhysician profile
Eric S Tiblier
NPI 1649241803
$4,308.33
in general payments reported to CMS, 2019-2025
30 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $512 · 2021: $546 · 2022: $806 · 2023: $836 · 2024: $701 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,347.96 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $965.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.50 | 2020-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $201.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $182.38 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $163.62 | 2019-2024 | |
| Esperion Therapeutics, INC. | $154.12 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $141.33 | 2023-2024 | Verquvo |
| Medtronic, INC. | $127.15 | 2023 | Corevalve Evolut R |
| Abbott Laboratories | $121.05 | 2021-2023 | Jot Dx |
| Medicure Pharma INC. | $120.76 | 2020-2021 | |
| Pfizer INC. | $91.39 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $51.32 | 2019-2021 | |
| Biosense Webster, INC. | $49.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $46.50 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $45.23 | 2021-2022 | |
| Biotronik INC. | $44.16 | 2020-2025 | Renamic Neo |
| Novo Nordisk INC | $37.08 | 2022-2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $30.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.28 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $24.81 | 2021 | |
| Agepha Pharma Fz LLC | $19.85 | 2024 | Lodoco |
| Vital Connect, INC | $16.56 | 2024 | Vitalpatch Rtm |
| Azurity Pharmaceuticals, INC. | $15.58 | 2025 | Edarbi |
| Atricure, INC. | $15.11 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2019 | |
| Impulse Dynamics (USA) INC. | $14.00 | 2022 | |
| Scpharmaceuticals INC. | $13.98 | 2024 | |
| Acist Medical Systems, INC. | $13.05 | 2023 | |
| Infobionic, INC | $6.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tiblier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.